Simulations Plus (NASDAQ:SLP) Rating Increased to Hold at Zacks Research

Key Points

• Simulations Plus has been upgraded to a "hold" rating by Zacks Research, while other analysts maintain mixed ratings with several price target adjustments recently reported.
• The company's stock has experienced fluctuations, with a recent closing price of $14.20 and a fifty-two week range between $12.39 and $37.72.
• Simulations Plus reported higher earnings per share of $0.45 for the last quarter, surpassing analysts' estimates, although revenue fell short of expectations at $20.36 million.

Simulations Plus (NASDAQ:SLP - Get Free Report) was upgraded by investment analysts at Zacks Research to a "hold" rating in a report issued on Tuesday,Zacks.com reports.

Several other analysts also recently commented on the stock. BTIG Research reduced their price objective on shares of Simulations Plus from $41.00 to $25.00 and set a "buy" rating for the company in a research report on Monday, July 7th. JMP Securities reaffirmed a "market perform" rating on shares of Simulations Plus in a research report on Wednesday, June 18th. William Blair reaffirmed an "outperform" rating on shares of Simulations Plus in a research report on Tuesday, July 15th. Wall Street Zen raised shares of Simulations Plus from a "sell" rating to a "hold" rating in a research report on Monday, April 28th. Finally, Craig Hallum reduced their price objective on shares of Simulations Plus from $45.00 to $36.00 and set a "buy" rating for the company in a research report on Friday, June 13th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $26.50.

Simulations Plus Stock Performance

NASDAQ:SLP opened at $14.20 on Tuesday. The company has a market capitalization of $285.85 million, a PE ratio of -4.51 and a beta of 0.76. The company has a 50 day simple moving average of $16.49 and a two-hundred day simple moving average of $25.69. Simulations Plus has a fifty-two week low of $12.39 and a fifty-two week high of $37.72.

Simulations Plus (NASDAQ:SLP - Get Free Report) last released its earnings results on Monday, July 14th. The technology company reported $0.45 earnings per share for the quarter, beating analysts' consensus estimates of $0.26 by $0.19. The business had revenue of $20.36 million during the quarter, compared to the consensus estimate of $22.83 million. Simulations Plus had a negative net margin of 78.63% and a positive return on equity of 11.62%. The company's revenue for the quarter was up 9.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.27 EPS. Research analysts predict that Simulations Plus will post 1.09 EPS for the current year.

Hedge Funds Weigh In On Simulations Plus

Large investors have recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in shares of Simulations Plus in the 2nd quarter worth $25,000. Fifth Third Bancorp lifted its holdings in shares of Simulations Plus by 33.8% in the 1st quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company's stock worth $36,000 after purchasing an additional 375 shares in the last quarter. Johnson Financial Group Inc. bought a new position in shares of Simulations Plus in the 4th quarter worth $39,000. AlphaQuest LLC bought a new position in Simulations Plus during the 2nd quarter valued at $69,000. Finally, Tower Research Capital LLC TRC lifted its stake in Simulations Plus by 42.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,575 shares of the technology company's stock valued at $72,000 after acquiring an additional 764 shares in the last quarter. 78.08% of the stock is currently owned by institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.